Ramsay Health Care Ltd (ASX: RHC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Ramsay Health Care Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Ramsay Health Care Ltd (ASX: RHC)
Latest News
Cheap Shares
Three ASX shares down 10% to 23%! Are they cheap?
Dividend Investing
Special dividends anyone? 5 ASX 200 stocks with excess franking credits
Healthcare Shares
ASX 200 healthcare stock surges amid new takeover rumours
Healthcare Shares
One 'oversold' ASX 200 healthcare share to buy today
Share Fallers
Why Appen, Dicker Data, Jupiter Mines, and Ramsay shares are dropping today
Earnings Results
Ramsay share price sinks 8% to 52-week low on disappointing FY24 results
Share Market News
5 things to watch on the ASX 200 on Friday
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Healthcare Shares
Guess which ASX 100 stock is expecting to report a 200% increase in profits
Broker Notes
Why the Woolworths share price could be a market beater
Frequently Asked Questions
-
Yes, Ramsay Health Care has historically paid two fully franked dividends a year.
-
Ramsay Health Care generally pays its shareholder dividends in March and September.
-
Ramsay Health Care Ltd listed on the ASX on 24 September 1997.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
04 Sep 2024 | $0.4000 | 100.00% | Final | 26 Sep 2024 |
11 Mar 2024 | $0.4000 | 100.00% | Interim | 05 Apr 2024 |
06 Sep 2023 | $0.2500 | 100.00% | Final | 29 Sep 2023 |
06 Mar 2023 | $0.5000 | 100.00% | Interim | 30 Mar 2023 |
05 Sep 2022 | $0.4850 | 100.00% | Final | 29 Sep 2022 |
07 Mar 2022 | $0.4850 | 100.00% | Interim | 31 Mar 2022 |
06 Sep 2021 | $1.0300 | 100.00% | Final | 30 Sep 2021 |
08 Mar 2021 | $0.4850 | 100.00% | Interim | 31 Mar 2021 |
05 Mar 2020 | $0.6250 | 100.00% | Interim | 27 Mar 2020 |
05 Sep 2019 | $0.9150 | 100.00% | Final | 30 Sep 2019 |
06 Mar 2019 | $0.6000 | 100.00% | Interim | 29 Mar 2019 |
05 Sep 2018 | $0.8650 | 100.00% | Final | 28 Sep 2018 |
06 Mar 2018 | $0.5750 | 100.00% | Interim | 29 Mar 2018 |
05 Sep 2017 | $0.0000 | 100.00% | Final | 28 Sep 2017 |
07 Mar 2017 | $0.5300 | 100.00% | Interim | 29 Mar 2017 |
06 Sep 2016 | $0.7200 | 100.00% | Final | 29 Sep 2016 |
08 Mar 2016 | $0.4700 | 100.00% | Interim | 30 Mar 2016 |
08 Sep 2014 | $0.5100 | 100.00% | Final | 24 Sep 2014 |
04 Mar 2014 | $0.3400 | 100.00% | Interim | 26 Mar 2014 |
03 Sep 2013 | $0.4150 | 100.00% | Final | 25 Sep 2013 |
04 Mar 2013 | $0.2900 | 100.00% | Interim | 27 Mar 2013 |
05 Mar 2012 | $0.2550 | 100.00% | Interim | 28 Mar 2012 |
02 Sep 2011 | $0.2950 | 100.00% | Final | 26 Sep 2011 |
08 Mar 2011 | $0.2250 | 100.00% | Interim | 28 Mar 2011 |
31 Aug 2010 | $0.2500 | 100.00% | Final | 27 Sep 2010 |
16 Mar 2010 | $0.1850 | 100.00% | Interim | 09 Apr 2010 |
21 Sep 2009 | $0.2150 | 100.00% | Final | 09 Oct 2009 |
20 Mar 2009 | $0.1650 | 100.00% | Interim | 08 Apr 2009 |
25 Sep 2008 | $0.1750 | 100.00% | Final | 15 Oct 2008 |
26 Sep 2007 | $0.1600 | 100.00% | Final | 12 Oct 2007 |
27 Mar 2006 | $0.1050 | 100.00% | Interim | 12 Apr 2006 |
26 Sep 2005 | $0.1150 | 100.00% | Final | 14 Oct 2005 |
16 Apr 2004 | $0.0750 | 100.00% | Interim | 30 Apr 2004 |
RHC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Ramsay Health Care Ltd
Ramsay Health Care Ltd (ASX: RHC) is one of the largest private healthcare providers in the world, with around 500 facilities across 11 countries. Its operations cover Australia, Europe, the UK, and Asia.
As well as private hospitals, Ramsay operates day surgeries, primary care clinics, diagnostic and imaging centres, mental health facilities, pharmacies, and an expanding range of in-home and community care services.
It is the largest private hospital group in Australia, France, and the Scandanavian countries. Its 52.5%-owned subsidiary Ramsay Sante oversees its European operations. Its UK business includes mental health facilities and a range of clinical specialties.
The vast majority of the company's revenue is generated from its Australian and European operations.
RHC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
13 Nov 2024 | $37.63 | $-0.79 | -2.06% | 420,038 | $38.02 | $38.15 | $37.63 |
12 Nov 2024 | $38.42 | $-0.01 | -0.03% | 804,657 | $38.47 | $38.60 | $38.06 |
11 Nov 2024 | $38.43 | $-0.29 | -0.75% | 374,196 | $38.62 | $38.95 | $38.38 |
08 Nov 2024 | $38.72 | $0.32 | 0.83% | 687,770 | $38.49 | $39.11 | $38.20 |
07 Nov 2024 | $38.40 | $0.12 | 0.31% | 536,061 | $38.37 | $38.65 | $37.97 |
06 Nov 2024 | $38.28 | $-0.99 | -2.52% | 430,418 | $39.68 | $39.81 | $38.17 |
05 Nov 2024 | $39.27 | $-0.22 | -0.56% | 269,255 | $39.28 | $39.56 | $39.10 |
04 Nov 2024 | $39.49 | $0.21 | 0.53% | 359,173 | $39.51 | $39.91 | $39.26 |
01 Nov 2024 | $39.28 | $-0.89 | -2.22% | 501,469 | $40.05 | $40.18 | $39.28 |
31 Oct 2024 | $40.17 | $-0.61 | -1.50% | 557,197 | $40.69 | $40.76 | $40.11 |
30 Oct 2024 | $40.78 | $-0.28 | -0.68% | 298,313 | $41.00 | $41.25 | $40.68 |
29 Oct 2024 | $41.06 | $-0.43 | -1.04% | 384,205 | $41.53 | $41.88 | $41.06 |
28 Oct 2024 | $41.49 | $-0.21 | -0.50% | 209,366 | $41.70 | $41.85 | $41.28 |
25 Oct 2024 | $41.70 | $-0.07 | -0.17% | 303,824 | $41.77 | $41.99 | $41.43 |
24 Oct 2024 | $41.77 | $-0.04 | -0.10% | 440,516 | $41.63 | $42.43 | $41.61 |
23 Oct 2024 | $41.81 | $0.13 | 0.31% | 291,738 | $41.70 | $42.08 | $41.45 |
22 Oct 2024 | $41.68 | $-0.72 | -1.70% | 501,757 | $42.10 | $42.24 | $41.67 |
21 Oct 2024 | $42.40 | $0.04 | 0.09% | 588,447 | $42.39 | $42.73 | $42.25 |
18 Oct 2024 | $42.36 | $-0.42 | -0.98% | 689,092 | $42.77 | $42.90 | $42.36 |
17 Oct 2024 | $42.78 | $0.20 | 0.47% | 735,317 | $43.10 | $43.30 | $42.70 |
16 Oct 2024 | $42.58 | $-0.76 | -1.75% | 816,291 | $42.93 | $43.05 | $42.51 |
15 Oct 2024 | $43.34 | $0.67 | 1.57% | 530,494 | $42.73 | $43.47 | $42.73 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
05 Sep 2024 | David Thodey | Buy | 2,475 | $100,485 |
On-market trade.
|
04 Sep 2024 | Helen Kurincic | Buy | 2,000 | $81,159 |
On-market trade.
|
04 Sep 2024 | Karen Penrose | Buy | 1,225 | $49,884 |
On-market trade.
|
28 Aug 2024 | Craig McNally | Expiry | 57,690 | $2,532,014 |
As advised by the company. Lapsed, 114,439 Rights
|
22 Dec 2023 | Claudia Dyckerhoff | Buy | 2,500 | $128,275 |
On-market trade.
|
15 Dec 2023 | Craig McNally | Issued | 64,625 | $3,261,623 |
Issue of securities. 172,129 Performance Rights
|
20 Nov 2023 | Karen Penrose | Buy | 195 | $9,935 |
On-market trade.
|
16 Nov 2023 | David Thodey | Buy | 4,000 | $210,509 |
On-market trade.
|
15 Nov 2023 | Karen Penrose | Buy | 665 | $34,972 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr David Ingle Thodey | Non-Executive DirectorNon-Executive Chairman | Nov 2017 |
Mr Thodey is a business leader focused on innovation, technology, digital transformation, and corporate governance, with more than 40 years of experience. In addition to being Chair of Ramsay, Mr Thodey is currently Chair of Xero Limited (a global cloud-based accounting solution for small and medium businesses). He is also Chancellor the University of Sydney, and co-Chair of the Great Barrier Reef Foundation.
|
Ms Catriona Alison Deans | Non-Executive Director | Nov 2018 |
Ms Deans has 25 years of experience building technology-enabled businesses involved in media, ecommerce, financial services, and health, and across leadership roles as an executive, a director and in venture capital. Ms Deans is also Chair of Cochlear Limited and a Non-Executive Director of Calix Limited, Fitness Passport and Deputy Pty Ltd. She is also a Venture Partner of Main Sequence Ventures.
|
Mr Michael Stanley Siddle | Non-Executive Director | May 1975 |
Mr Siddle has experience in the management of private hospitals and has been integrally involved in Ramsay Health Care's expansion through developments, mergers, and acquisitions.
|
Mr Craig Ralph McNally | Chief Executive OfficerManaging Director | Jul 2017 |
Mr McNally has worked across operational, strategic, and financial roles. For the past two decades, Mr McNally has been responsible for the development and implementation of its growth strategy including brownfield expansions, international market assessments, mergers and acquisitions and new business strategies. He has been at the forefront of all the acquisitions and deals.
|
Ms Helen Kurincic | Non-Executive Director | Mar 2024 |
Ms Kurincic brings operational, executive, and board-level experience in a range of Australian based healthcare organisations. In addition to serving on the Ramsay Board, Ms Kurincic is currently Chair of McMillan Shakespeare and a director of Carlton Football Club. Ms Kurincic's previous health sector roles include Non-Executive Director of private health insurer HBF Health, Estia Health, Integral Diagnostics (Chair), Sirtex Medical, Domain Principal Group, public hospital service provider Melbourne Health, Orygen Youth Mental Health Research Centre and DCA Group.
|
Ms Karen Lee Collett Penrose | Non-Executive Director | Mar 2020 |
Ms Penrose has had an executive career in leadership and CFO roles, mainly in financial services. She is familiar in financial management, customer outcomes and operating in a rapidly changing regulatory environment which stems from 20 years in banking with Commonwealth Bank and HSBC and eight years as a listed-company CFO. She is also a member of the Risk Management Committee.
|
Mr Steven Andrew Sargent | Non-Executive Director | Nov 2021 |
Mr Sargent is Chair of the Risk Management Committee. His executive career included 22 years at General Electric, where he gained multi-industry, international experience leading businesses in industries including healthcare, energy and financial services across the USA, Europe and Asia Pacific. Mr Sargent is currently a Non-Executive Director of Origin Energy Limited and Chair of infection prevention company Nanosonics Limited.
|
Ms Claudia Ricarda Rita Sussmuth Dyckerhoff | Non-Executive Director | Oct 2018 |
Ms Dyckerhoff bringing expertise in market growth strategies, business development and operational performance improvement in hospitals. Dr Sussmuth Dyckerhoff has global experience in hospitals and health care across Europe, Asia, and the USA. She joined McKinsey and Company in Switzerland in 1995 and transferred to the USA focusing on supporting health care companies, including pharmaceutical/medical device companies, payor, provider and health systems in Europe and the USA. In 2006, Dr Sussmuth Dyckerhoff transferred to China, was elected Senior Partner in 2010 and supported health care companies as well as governments across Asia. She is also a member of the Risk Management Committee.
|
Mr James Malcolm McMurdo | Non-Executive Director | Sep 2019 |
Mr McMurdo has more than 30 years of finance and banking experience. He has a background in corporate advisory spanning across mergers and acquisitions, strategic advisory and financing with experience across multiple industries including the healthcare sector. He has held senior operating management roles and worked extensively in both the Asia Pacific and European regions. Mr McMurdo is one of the Founding Partners of Privatus Capital Partners, an advisory and merchant banking business. Prior to establishing Privatus, he held senior management roles at Deutsche Bank and was based in Hong Kong. In the time he was at Deutsche Bank, Mr McMurdo was Global Co-Head of Corporate Finance, Head of Corporate and Investment Bank for Asia Pacific and CEO for Australia and New Zealand.
|
Ms Henrietta Rowe | Company SecretaryGroup General Counsel | Jun 2019 |
-
|
Henrietta Rowe | Company SecretaryGroup General Counsel |
-
|
|
Martyn Roberts | Group Chief Financial Officer |
-
|
|
Collen Harris | Group Chief People Officer |
-
|
|
Andrew Wearne | Group Chief Risk Officer |
-
|
|
Rachna Gandhi | Group Chief Transformational and Digital Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 51,231,592 | 22.30% |
J P Morgan Nominees Australia Pty Limited | 34,633,790 | 15.07% |
Netwealth Investments Limited <Wrap Services A/C> | 23,452,113 | 10.21% |
Paul Ramsay Holdings Pty Limited | 19,495,410 | 8.48% |
Citicorp Nominees Pty Limited | 19,340,054 | 8.42% |
National Nominees Limited | 4,675,258 | 2.04% |
Woolwich Investments Pty Ltd <The Siddle Family Trust> | 2,750,000 | 1.20% |
BNP Paribas Noms Pty Ltd | 2,655,835 | 1.16% |
Washington H Soul Pattinson And Company Limited | 2,320,085 | 1.01% |
BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 2,098,434 | 0.91% |
Argo Investments Limited | 2,033,197 | 0.89% |
BNP Paribas Nominees Pty Ltd <Agency Lending Collateral > | 1,663,500 | 0.72% |
Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 1,645,543 | 0.72% |
Custodial Services Limited <Beneficiaries Holding A/C> | 1,632,137 | 0.71% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 1,327,444 | 0.58% |
BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 1,017,896 | 0.44% |
HSBC Custody Nominees (Australia) Limited Gsi Eda | 1,000,138 | 0.43% |
Australian Foundation Investment Company Limited | 1,000,000 | 0.43% |
UBS Nominees Pty Ltd | 897,160 | 0.39% |
Certane Ct Pty Ltd <Ramsay Unallocated Ac> | 778,088 | 0.34% |